The Cytokines and Depression Hypothesis: An Evaluation

NeuroImmune Biology

Volumn 6, Issue C, 2008, Pages 485-506

  Dunn, Adrian J ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957079929     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(07)10023-5     Document Type: Review

References (143)

1. Hart B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (1988) 123-137
2. Smith R.S. The macrophage theory of depression. Med Hypotheses 35 (1991) 298-306
3. Kent S., Bluthé R.-M., Kelley K.W., and Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13 (1992) 24-28
4. Dunn A.J., Swiergiel A.H., and de Beaurepaire R. Cytokines as mediators of depression: What we can learn from animal studies?. Neurosci Biobehav Rev 29 (2005) 891-909
5. Weisse C.S. Depression and immunocompetence: A review of the literature. Psychol Bull 111 (1992) 475-489
6. Kronfol Z. Immune dysregulation in major depression: A critical review of existing evidence. Int J Neuropsychopharmacol 5 (2002) 333-343
7. Irwin M., and Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 21 (2007) 374-383
8. Valentine A.D., Meyers C.A., Kling M.A., Richelson E., and Hauser P. Mood and cognitive side-effects of interferon-α therapy. Semin Oncol 25 (1998) S39-S47
9. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 461 (1999) 75-81
10. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X., and Lee B.-N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97 (2003) 2919-2925
11. de Beaurepaire R., Swiergiel A.H., and Dunn A.J. Neuroimmune mediators: Are cytokines mediators of depression. In: Licinio J., and Wong M.-L. (Eds). In Biology of Depression (2005), Weinheim:Wiley 557-581
12. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., and Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 156 (1999) 1120
13. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., and Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 (2001) 961-966
14. Capuron L., Ravaud A., Neveu P., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7 (2002) 468-473
15. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 11-38
16. Maes M., Lambrechts J., Bosmans E., Jacobs J., Suy E., Vandervorst C., de Jonckheere C., Minner B., and Raus J. Evidence for a systemic immune activation during depression, results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22 (1992) 45-53
17. Maes M. Major depression and activation of the inflammatory response system. In: Dantzer R., Wollman E.E., and Yirmiya R. (Eds). In Cytokines, Stress, and Depression (1999), Kluwer Academic/Plenum Publishers, New York 25-46
18. Kronfol Z., and House J.D. Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 80 (1989) 142-147
19. Anisman H., Ravindran A.V., Griffiths J., and Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4 (1999) 182-188
20. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., and Kirchner H. Cytokine production and serum proteins in depression Scand. J Immunol 41 6 (1995) 534-538
21. Dunbar P.R., Hill J., Neale T.J., and Mellsop G.W. Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med 22 (1992) 1051-1057
22. Landmann R., Schaub B., Link S., and Wacker H.R. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biol Psychiatry 15 (1997) 675-681
23. Natelson B.H., Denny T., Zhou X.D., LaManca J.J., Ottenweller J.E., Tiersky L., et al. Is depression associated with immune activation?. J Affect Disord 53 (1999) 179-184
24. Maes M., Scharpé S., Meltzer H., Bosmans E., Suy E., Calabrese J., and Cosyns P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49 (1993) 11-27
25. Maes M., Bosmans E., Scharpé S., Meltzer H.Y., and Suy E. Interleukin-1β: A putative mediator of HPA axis hyperactivity in major depression?. Am J Psychiatry 150 (1993) 1189-1193
26. Maes M., Meltzer H.Y., and Bosman E. Psychoimmune investigation in obsessive-compulsive disorder: Assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations. Neuropsychobiology 30 (1994) 57-60
27. Griffiths J., Ravindran A.V., Merali Z., and Anisman H. Neuroendocrine measures and lymphocyte subsets in depressive illness: Influence of a clinical interview concerning life experiences. Psychoneuroendocrinology 22 (1997) 225-236
28. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43 (1991) 425-473
29. Brambilla F., and Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 97 (1998) 309-313
30. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., and Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. Am J Psychiatry 158 (2001) 1252-1257
31. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., and Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 33 (1999) 407-418
32. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., and Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40 (1999) 171-176
33. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., and Schmidt K. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 15 (2001) 199-226
34. Pollmächer T., Haack M., Schuld A., Reichenberg A., and Yirmiya R. Low levels of circulating inflammatory cytokines - Do they affect human brain functions?. Brain Behav Immun 16 (2002) 525-532
35. Minden S.L., and Schiffer R.B. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 47 (1990) 98-104
36. Marshall P.S. Allergy and depression, a neurochemical threshold model of the relation between the illnesses. Psychol Bull 113 (1993) 23-43
37. Dickens C., McGowan L., Clark-Carter D., and Creed F. Depression in rheumatoid arthritis, a systematic review of the literature with meta-analysis. Psychosom Med 64 (2002) 52-60
38. Schwartz J.A., Speed N.M., Brunberg J.A., Brewer T.L., Brown M., and Greden J.F. Depression in stroke rehabilitation. Biol Psychiatry 33 (1993) 694-699
39. Foley F.W., Traugott U., LaRocca N.G., Smith C.R., Perlman K.R., Caruso L.S., and Scheinberg L.C. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 49 (1992) 238-244
40. Dantzer R., Bluthé R.-M., Castanon N., Chauvet N., Capuron L., Goodall G., Kelley K.W., Konsman J.-P., Layé S., Parnet P., and Pousset F. Cytokine effects on behavior. In: Ader R., Felten D., and Cohen N. (Eds). In Psychoneuroimmunology. 3rd Edn. (2001), Academic Press, San Diego, CA 703-727
41. Nesse R.M. Is depression an adaptation?. Arch Gen Psychiatry 57 (2000) 14-20
42. Dubrovsky B. Evolutionary psychiatry. Adaptationist and nonadaptationist conceptualizations. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1-19
43. Dietzel M., Saletu B., Lesch O.M., Sieghart W., and Schjerve M. Light treatment in depressive illness: Polysomnographic, psychometric, and polyendocrinal findings. Eur Neurol 25 Suppl 2 (1986) 93
44. McCarthy D.O., Kluger M.J., and Vander A.J. Effect of centrally administered interleukin-1 and endotoxin on food intake of fasted rats. Physiol Behav 36 (1986) 745-749
45. Swiergiel A.H., Smagin G.N., and Dunn A.J. Influenza virus infection of mice induces anorexia: Comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacol Biochem Behav 57 (1997) 389-396
46. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., and Maier S.F. Characterization of cytokine-induced hyperalgesia. Brain Res 654 (1994) 15-26
47. Krueger J.M., and Majde J.A. Microbial products and cytokines in sleep and fever regulation. Crit Rev Immmunol 14 (1995) 355-379
48. Merali Z., Brennan K., Brau P., and Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1b: Antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology 165 (2003) 413-418
49. Yirmiya R., Weidenfeld J., Pollak Y., Morag M., Morag A., Avitsur R., Barak O., Reichenberg A., Cohen E., Shavit Y., and Ovadia H. Cytokines, "Depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol 461 (1999) 283-316
50. De La Garza R. Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: Focus on anhedonia. Neurosci Behav Rev 29 (2005) 761-770
51. Anisman H., Kokkinidis L., and Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res 731 (1996) 1-11
52. Anisman H., Kokkinidis L., Borowski T., and Merali Z. Differential effects of interleukin (IL)-1β, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 779 (1998) 177-187
53. Hebb A., Zacharko R.M., and Anisman H. Self-stimulation from the mesencephalon following intraventricular interleukin-2 administration. Brain Res Bull 45 (1998) 549-556
54. Larson S.J., and Dunn A.J. Behavioral effects of cytokines. Brain Behav Immun 15 (2001) 371-387
55. McKenna P.J., McKay A.P., and Laws K. Memory in functional psychosis. In: Berrios G.E., and Hodges J.R. (Eds). In Memory Disorders in Psychiatric Practice (2000), Cambridge University Press, Cambridge
56. Watkins L.R., Maier S.F., and Goehler L.E. Cytokine-to-brain communication: A review and analysis of alternative mechanisms. Life Sci 57 (1995) 1011-1026
57. Bluthé R.-M., Michaud B., Kelley K.W., and Dantzer R. Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. NeuroReport 7 (1996) 1485-1488
58. Licinio J., and Wong M.-L. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 4 (1999) 317-327
59. Goehler L.E., Relton J.K., Dripps D., Kiechle R., Tartaglia N., Maier S.F., and Watkins L.R. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist (IL-1ra) in the rat: A possible mechanism for immune-to-brain communication. Brain Res Bull 43 (1997) 357-364
60. Wieczorek M., Pournajafi-Nazarloo H., Swiergiel A.H., and Dunn A.J. Physiological and behavioral responses to interleukin-1b and LPS in vagotomized mice. Physiol Behav 84 (2005) 500-511
61. Wieczorek M., and Dunn A.J. Effect of subdiaphragmatic vagotomy on the noradrenergic and HPA axis activation induced by intraperitoneal interleukin-1 administration in rats. Brain Res 1101 (2006) 73-84
62. Swiergiel A.H., Burunda T., Patterson B., and Dunn A.J. Endotoxin- and interleukin-1-induced hypophagia are not affected by noradrenergic, dopaminergic, histaminergic and muscarinic antagonists. Pharmacol Biochem Behav 63 (1999) 629-637
63. Quan N., and Herkenham M. Connecting cytokines and brain: A review of current issues. Histol Histopathol 17 (2002) 273-288
64. Blatteis C.M., Li S., Li Z., Feleder C., and Perlik V. Cytokines, PGE2 and endotoxic fever: A re-assessment. Prostaglandins Other Lipid Mediat 76 (2005) 1-18
65. Dunn A.J., Swiergiel A.H., Zhang H., and Quan N. The hypophagia induced by interleukin-1 and lipopolysaccharide is associated with induction of cyclooxygenase-2 in brain endothelia. Neuroimmunomodulation 13 (2006) 96-104
66. Breder C.D., Dinarello C.A., and Saper C.B. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 240 (1988) 321-324
67. Lechan R.M., Toni R., Clark B.D., Cannon J.G., Shaw A.R., Dinarello C.A., et al. Immunoreactive interleukin-1β localization in the rat forebrain. Brain Res 514 (1990) 135-140
68. Molenaar G.J., Berkenbosch F., van Dam A.-M., and Lugard C. Distribution of interleukin 1β immunoreactivity within the porcine hypothalamus. Brain Res 608 (1993) 169-174
69. Huitinga I., van der Cammen M., Salm L., Erkut Z., van Dam A.-M., Tilders F., and Swaab D. IL-1β immunoreactive neurons in the human hypothalamus: Reduced numbers in multiple sclerosis. J Neuroimmunol 107 (2000) 8-20
70. Layé S., Parnet P., Goujon E., and Dantzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Mol Brain Res 27 (1994) 157-162
71. Wong M.-L., and Licinio J. Localization of interleukin-1 type I receptor mRNA in rat brain. Neuroimmunomodulation 1 (1994) 110-115
72. Wong M.L., Bongiorno P.B., Rettori V., McCann S.M., and Licinio J. Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proc Natl Acad Sci 94 (1997) 227-232
73. Quan N., Whiteside M., and Herkenham M. Time course and localization patterns of interleukin-1β messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience 83 (1998) 281-293
74. Quan N., Sundar Q.N., and Weiss J.M. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J Neuroimmunol 49 (1994) 125-134
75. Van Dam A.M., Bauer J., Tilders F.J.H., and Berkenbosch F. Endotoxin-induced appearance of immunoreactive interleukin-1b in ramified microglia in rat brain: A light and electron microscopic study. Neuroscience 65 (1995) 815-826
76. Quan N., Zhang Z., Emery M., Bonsall R., and Weiss J.M. Detection of interleukin-1 bioactivity in various brain regions of normal healthy rats. Neuroimmunomodulation 3 (1996) 47-55
77. Farrar W.L., Kilian P.L., Ruff M.R., Hill J.M., and Pert C.B. Visualization and characterization of interleukin 1 receptor in brain. J Immunol 139 (1987) 459-463
78. Haour F., Ban E., Marquette C., Milon G., and Fillion G. Brain interleukin-1 receptors: Mapping, characterization and modulation. In: Rothwell N.J., and Dantzer R.D. (Eds). In Interleukin-1 in the Brain (1992), Pergamon Press, Oxford 13-25
79. 125I] recombinant human interleukin-1 receptor antagonist. J Neuroimmunol 41 (1992) 51-60
80. Krakauer J.V., and Oppenheimer J.J. Pro-inflammatory cytokines. TNF and IL-1 families, chemokines, TGF-beta and others. In: Paul W.E. (Ed). In Fundamental Immunology (1999), Lippincott-Raven, Philadelphia, PA 775-811
81. Yabuuchi K., Minami M., Katsumata S., and Satoh M. Localization of type 1 interleukin-1 receptor mRNA in the rat brain. Mol Brain Res 27 (1994) 27-36
82. Ericsson A., Liu C., Hart R.P., and Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 361 4 (1995) 681-698
83. Dantzer R., Aubert A., Bluthé R.-M., Gheusi G., Cremona S., Layé S., Konsman J., Parnet P., and Kelley K.W. Mechanisms of the behavioural effects of cytokines. Adv Exp Med Biol 461 (1999) 83-105
84. Pugh C.R., Nguyen K.T., Gonyea J.L., Fleshner M., Watkins L.R., Maier S.F., and Rudy J.W. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 106 (1999) 109-118
85. Borsody M.K., and Weiss J.M. The effects of endogenous interleukin-1 bioactivity on locus coeruleus neurons in response to bacterial and viral substances. Brain Res 1007 (2004) 39-56
86. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 711 (1996) 163-174
87. Shen Y., Connor T.J., Nolan Y., Kelly J.P., and Leonard B.E. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 65 (1999) 1773-1786
88. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., Weihe E., and Weidenfeld J. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24 (2001) 531-544
89. Castanon N., Konsman J.-P., Medina C., Chauvet N., and Dantzer R. Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation. Psychoneuroendocrinology 28 (2003) 19-34
90. Dunn A.J., and Swiergiel A.H. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation 9 (2001) 163-169
91. Connor T.J., Harkin A., Kelly J.P., and Leonard B.E. Olfactory bulbectomy provokes a suppression of interleukin-1b and tumour necrosis factor-a production in response to an in vivo challenge with lipopolysaccharide: Effect of chronic desipramine treatment. Neuroimmunomodulation 7 (2000) 27-35
92. Campisi J., Hansen M.K., O'Conner K.A., Biedenkapp J.C., Watkins L.R., Maier S.F., and Fleshner M. Circulating cytokines and endotoxin are not necessary for the activation of the sickness or corticosterone response produced by peripheral E. coli challenge. J Appl Physiol 95 (2003) 1873-1882
93. Besedovsky H.O., del Rey A., Sorkin E., and Dinarello C.A. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233 (1986) 652-654
94. Strohle A., and Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36 Suppl 3 (2003) S207-S214
95. Silverman M.N., Pearce B.D., and Miller A.H. Cytokines and HPA axis regulation. In: Kronfol Z. (Ed). In Cytokines and Mental Health (2003), Kluwer Academic Publishers, Norwell, MA 85-122
96. Dunn A.J. Cytokine activation of the hypothalamo-pituitary-adrenal axis. In: Steckler T., Kalin N., and Reul J.M.H.M. (Eds). In Handbook of Stress and the Brain Part 2: Stress: Integrative and Clinical Aspects (2005), Elsevier, Amsterdam 157-174
97. Wang J.P., and Dunn A.J. The role of interleukin-6 in the activation of the hypothalamo- pituitary-adrenocortical axis induced by endotoxin and interleukin-1b. Brain Res 815 (1999) 337-348
98. Swiergiel A.H., and Dunn A.J. Feeding, exploratory, anxiety- and depression-related behaviors are not altered in interleukin-6-deficient male mice. Behav Brain Res 171 (2006) 94-108
99. Silverman M.N., Miller A.H., Biron C.A., and Pearce B.D. Characterization of an interleukin-6 and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology 145 (2004) 3580-3589
100. Shimizu H., Ohtani K.-I., Sato N., Nagamine T., and Mori M. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-α administration. Endocr J 42 (1995) 551-556
101. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., and Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160 (2003) 1342-1345
102. Holsboer F., Stalla G.K., von Bardeleben U., Hammann K., Müller H., and Müller O.A. Acute adrenocortical stimulation by recombinant gamma interferon in human controls. Life Sci 42 (1988) 1-5
103. Saphier D. Neurophysiological and endocrine consequences of immune activity. Psychoneuroendocrinology 14 (1989) 63-87
104. 1-opioid receptors in the rat. Eur J Pharmacol 236 (1993) 183-191
105. Menzies R.A., Phelps C.P., Wiranowska M., Oliver J., Chen L.T., Horvath E., and Hall N.R.S. The effect of interferon-alpha on the pituitary-adrenal axis. J Interferon Cytokine Res 16 (1996) 619-629
106. Dunn A.J. The role of interleukin-1 and tumor necrosis factor a in the neurochemical and neuroendocrine responses to endotoxin. Brain Res Bull 29 (1992) 807-812
107. Dunn A.J., and Swiergiel A.H. The role of cyclooxygenases in endotoxin- and interleukin- 1-induced hypophagia. Brain Behav Immun 14 (2000) 141-152
108. Dunn A.J., and Chuluyan H. The role of cyclo-oxygenase and lipoxygenase in the interleukin-1-induced activation of the HPA axis: Dependence on the route of injection. Life Sci 51 (1992) 219-225
109. Dunn A.J. Role of cytokines in infection-induced stress. Ann N Y Acad Sci 697 (1993) 189-202
110. Turnbull A.V., and Rivier C. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: Actions and mechanisms of action. Physiol Rev 79 (1999) 1-71
111. Muglia L.J., Bethin K.E., Jacobson L., Vogt S.K., and Majzoub J.A. Pituitary-adrenal axis regulation in CRH-deficient mice. Endocr Res 26 (2000) 1057-1066
112. Dunn A.J., and Swiergiel A.H. Behavioral responses to stress are intact in CRF-deficient mice. Brain Res 845 (1999) 14-20
113. Dunn A.J. Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone. Life Sci 43 (1988) 429-435
114. Dunn A.J. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6 (2006) 52-68
115. Wang J.P., and Dunn A.J. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 33 (1998) 143-154
116. Ando T., and Dunn A.J. Mouse tumor necrosis factor-α increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation 6 (1999) 319-329
117. Dunn A.J. Effects of cytokines and infections on brain neurochemistry. In: Ader R., Felten D.L., and Cohen N. (Eds). In Psychoneuroimmunology. 3rd Edn. (2001), Academic Press, New York 649-666
118. Wong M.L., Kling M.A., Munson P.J., Listwak S., Licinio J., Prolo P., Karp B., McCutcheon I.E., Geracioti T.D., DeBellis M.D., Rice K.C., Goldstein D.S., Veldhuis J.D., Chrousos G.P., Oldfield E.H., McCann S.M., and Gold P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci 97 (2000) 325-330
119. Bell C., Abrams J., and Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178 (2001) 399-405
120. Coppen A., and Wood K. Tryptophan and depressive illness. Psychol Med 8 (1978) 49-57
121. Wichers M.C., and Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 29 (2004) 11-17
122. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat Med 7 (2001) 541-547
123. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., and Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643 (1994) 40-49
124. Clement H.W., Buschmann J., Rex S., Grote C., Opper C., Gemsa D., and Wesemann W. Effects of interferon-γ, interleukin-1β, and tumor necrosis factor-α on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm. 104 (1997) 981-991
125. Zhang J.-J., Terreni L., De Simoni M.-G., and Dunn A.J. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 38 (2001) 303-308
126. Hayley S., Wall P., and Anisman H. Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-α: Peripheral and central mechanisms. Eur J Neurosci 15 (2002) 1061-1076
127. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
128. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., and Charney D.S. Serotonin and the neurobiology of depression - Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51 (1994) 865-874
129. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Moreno F.A., and Charney D.S. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46 (1999) 212-220
130. O'Reardon J.P., Chopra M.P., Bergan A., Gallop R., DeRubeis R.J., and Crits-Christoph P. Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants. Biol Psychiatry 55 (2004) 957-959
131. Moreno F.A., Heninger G.R., McGahuey C.A., and Delgado P.L. Tryptophan depletion and risk of depression relapse: A prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 48 (2000) 327-329
132. Blokland A., Lieben C.K.J., and Deutz N. Anxiogenic and depressive-like effects, but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. J Psycho-pharmacol 16 (2002) 39-49
133. Lieben C.K.J., van Oorsouw K., Deutz N., and Blokland A. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav Brain Res 151 (2004) 53-64
134. Uehara A., Ishikawa Y., Okumura T., Okamura K., Sekiya C., Takasugi Y., and Namiki M. Indomethacin blocks the anorexic action of interleukin-1. Eur J Pharmacol 170 (1989) 257-260
135. Bluthé R.M., Crestani F., Kelley K.W., and Dantzer R. Mechanisms of the behavioral effects of interleukin 1. Role of prostaglandins and CRF. Ann N Y Acad Sci 650 (1992) 268-275
136. Charlton B.G. The malaise theory of depression: Major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses 54 (2000) 126-130
137. McCarthy D.O., and Daun J.M. The effects of cyclooxygenase inhibitors on tumor-induced anorexia in rats. Cancer 71 (1993) 486-492
138. Jain N.K., Kulkarni S.K., and Singh A. Lipopolysaccharide-mediated immobility in mice: Reversal by cyclooxygenase enzyme inhibitors. Meth Find Exp Clin Pharmacol 23 (2001) 441-444
139. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn 229 (1977) 327-336
140. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
141. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 85 (1985) 367-370
142. Dunn A.J., and Swiergiel A.H. Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 81 (2005) 688-693
143. Deak T., Bellamy C., D'Agostino L.G., Rosanoff M., McElderry N.K., and Bordner K.A. Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide. Behav Brain Res 160 (2005) 125-134